Effect of tamsulosin on ejaculatory function in BPH/LUTS

Abstract

This study was undertaken to determine the impact on ejaculatory function of tamsulosin (0.2 mg) given once daily (OD) for 12 weeks and to identify risk factors for ejaculatory dysfunction in patients undergoing this treatment. Males with an International Prostatic Symptom Score (IPSS) o8 were enrolled in this study. All participants completed questionnaires, including the IPSS and the Male Sexual Health Questionnaire (MSHQ), and serum prostate-specific antigen, transrectal ultrasound and uroflowmetry with post-void residual were measured. After initiating 0.2 mg OD tamsulosin, patients were re-evaluated on the fourth and twelfth weeks of medication. The chi-squared test, the independent t-test and one-way ANOVA were used to compare means. Binary logistic regression analysis was used to calculate the odds ratio for all risk factors. A total of 177 men constituted the study cohort. No significant difference was observed between baseline and follow-up for the erectile function, ejaculatory function, satisfaction, sexual activity and desire domains (EFD, EjFD, SDA and ADD) or for erectile or ejaculatory bother mean scores. After 12 weeks, the overall incidence of ejaculatory dysfunction (EjD) was 13.4%. Incidences of the seven different types of EjD (decreased frequency, delay, dryness, decreased strength/force, decreased volume, decreased pleasure and pain at ejaculation) were 2.4%, 3.1%, 3.9%, 3.9%, 6.3%, 7.1% and 3.1%, respectively. Baseline EjFD scores were higher for IPSS responders than for non-responders (26.09 vs. 24.06, P50.03). An EjFD score reduction was more frequent in IPSS responders. The incidence of EjD was small, but not negligible and was more frequent in patients with less lower urinary tract symptoms, a smaller prostate, higher baseline MSHQ totals and higher EjFD scores.

The role of sympathetic and parasympathetic nerve systems on the smooth muscle of rat seminal vesicles – experimental results and speculation for physiological implication on ejaculation

“…Our previous in vivo study demonstrated that sympatholytic agents could decrease the SV contractile reaction to electrical stimulation of the lesser splanchnic nerve, and the α1a antagonist, WB‐4101, had therapeutic potential for pre‐mature ejaculation (Hsieh et al ., ). Some clinical studies have already found that the α1a antagonist, tamsulosin, contributed to different types of ejaculatory dysfunction (Song et al ., ). The α1a receptor distribution on SV was also confirmed by mRNA expression (Hisasue et al ., ).…”

The role of urethral pressure profile on treating premature ejaculation by tamsulosin

“…Recent study was undertaken to determine the impact of tamsulosin (0.2 mg once daily for 12 weeks) on ejaculatory function. The overall incidence of ejaculatory dysfunction was 13.4%, and the incidence of abnormal ejaculation was more frequent in patients with less LUTS, higher baseline Male Sexual Health Questionnaire totals, and smaller prostate volumes 10. In our study, 13% patients treated by tamsulosin reported discomfort on orgasm and anejaculation.…”

A Study on Efficacy and Safety of Silodosin in Geriatric Patients with Benign Prostatic Hyperplasia

“…However Chapple et al [21] reported that the frequency of ejaculation disorder was 14.2% in the silodosin treatment group, which was also significantly higher compared with 2.1 in the 0.4 mg tamsulosin treatment group. Song et al [22] reported that the overall incidence of ejaculatory dysfunction was 13.4% after 12 weeks of 0.2 mg tamsulosin treatment.…”

“…A recent RCT [21] suggested that compared with tamsulosin or placebo, silodosin showed no significant differences in the supine systolic blood pressure, diastolic blood pressure and heart rate. α1B-adrenoreceptors have been demonstrated to mediate both blood vessel contraction and baroreceptor-induced inotropic effects [25,26,27].…”